KUALA LUMPUR: Texchem Resources Bhd (TRB) signed a letter of intent (LoI) with CellSource Co Ltd (CCL) to establish a joint venture (JV) to introduce the latter's platelet-derived factor concentrate freeze-dry (PFC-FDTM) processing service, which is patented both in Malaysia and Japan, to medical institutions in Malaysia.
TRB executive chairman Tan Sri (Dr) Fumihiko Konishi said the company's
in-house team has a proven track record of serving the medical/life sciences sectors and has multiple certifications validating its expertise and commitment to excellence.
"This places us in an excellent position to join forces with CCL and introduce its PFC-FDTM processing service to medical
institutions throughout Malaysia and beyond.
"By combining our expertise and resources, we aim to bring regenerative solutions to the healthcare landscape in the country," he said in a statement.
CCL is a regenerative medicine specialist listed on the Tokyo Stock Exchange Growth Market, offering processing services for platelet-rich plasma derived from patients' blood.
Using a patented and innovative process, CCL concentrates on the growth factors present in PRP to create platelet-derived PFC-FDTM.
This process allows PFC-FDTM to be stored at room temperature for an extended duration, ensuring its long-term viability and effectiveness.
CCL's PFC-FDTM processing services will be made available in Malaysia subject to regulatory approvals by Malaysia's National Pharmaceutical Regulatory
Agency.
TRB and CCL plan to establish a JV in Malaysia by the end of 2023.
CCL chief executive officer and representative director Masato Tsumamoto said this signing represents a key milestone for the company as it marks CCL's first JV business overseas as part of its geographical expansion.
"Malaysia serves as our initial destination, chosen for its potential in medical tourism, further bolstered by the establishment and support of the Malaysia Healthcare Travel Council.
"Therefore, we are delighted to have TRB as a partner to capitalise on these vast opportunities together.
"More importantly, we are committed to utilising our collective expertise and resources to deliver groundbreaking regenerative solutions that will positively impact patient outcomes and advance the field of regenerative medicine in Malaysia and beyond," he said.